Review of GLP-1 agonist new perspectives in T2D covers updated glycemic and weight management evidence, emerging formulations, and expanded indications.
Key findingReview of GLP-1 agonist new perspectives in T2D covers updated glycemic and weight management eviden
What the researchers found
Review of GLP-1 agonist new perspectives in T2D covers updated glycemic and weight management evidence, emerging formulations, and expanded indications.
Why it matters
Relevant to peptide-based therapeutic applications.
The numbers in context
Obesity affects 988 million people and T2DM 537 million globally, with figures continuously increasing.
How the study worked
Methodology in publication.
Who was studied
Adults with obesity and type 2 diabetes across reviewed clinical trials
What this study cannot tell us
Limitations in publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Contributes to peptide therapeutic evidence.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
GLP-1 agonists in glycemic and weight control of type 2 diabetes. New perspectives.
Medicina clinica, 165(3), 107042
Citation
Alonso, Silvia Patricia; Valdes, Sergio; Doulatram-Gamgaram, Viyey Kishore. (2025). GLP-1 agonists in glycemic and weight control of type 2 diabetes. New perspectives.. Medicina clinica, 165(3), 107042. https://doi.org/10.1016/j.medcli.2025.107042